Short answer. For BPC-157, the policy describes enforcement discretion for the acetate, by subcutaneous, intramuscular, oral, or topical routes, when every other condition is also met [2]. That is not FDA approval. As of Oct 29, 2026.

The identity Appendix B prints

Appendix B identifies BPC-157 acetate with molecular formula C62H98N16O22·xCH3COOH and molecular weight 1419.54 plus the acetate contribution. The amino acid sequence it prints is the 15-residue sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, as the acetate [2]. A product has to match that identity, not just the nickname BPC-157 [2].

The policy says both the free base and the acetate were in Category 2 from September 2023 until April 22, 2026, and that neither placement nor removal changed their status under section 503A [2]. It says FDA's Center for Drug Evaluation and Research recommended against listing either form, and the Pharmacy Compounding Advisory Committee voted in favor of inclusion [2].

The discretion sentence that follows is about the acetate, and about four dosage forms: subcutaneous, intramuscular, oral, and topical, compounded from an ingredient with a certificate of analysis that meets the policy [2]. A route that is not in that sentence is not what this policy describes.

What HHS offered as its reason

HHS points to documented historical use, human studies, and lot-specific certificates from an FDA-registered facility that report identity, impurity, endotoxin, microbial, and residual-solvent results [2]. Those are HHS's reasons for discretion. They are not an FDA finding that BPC-157 heals injuries. FDA's July 2026 briefing, summarized on BPC-157 vs TB-500, still treated the human studies as small. Read both. Do not collapse them into "it works."

Oral BPC-157 is one of the routes named, and oral forms have an extra condition: the compounder keeps documentation that the specific formulation reaches adequate oral bioavailability in people [2]. That paperwork is the compounder's. It is not a dose.

Sommar Club does not prescribe or sell BPC-157. The evidence page is BPC-157. The announcement hub is HHS and 6 peptides: what changed.

FAQ

Is BPC-157 FDA-approved now? No [1].

Does the policy cover every BPC-157 product online? No. It describes licensed compounders, the acetate, named routes, and the other conditions [1][2].

Sources

1. HHS notice, FR Doc. 2026-22192, filed Oct 28, 2026. https://public-inspection.federalregister.gov/2026-22192.pdf

2. HHS policy, Appendix B, BPC-157. https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf

Education only. Not medical or legal advice. As of Oct 29, 2026.